ClinicalTrials.gg

Program

nuvisertib

Also written as “TP-3654”, “Nusivertib” and “TP 3654”.

Its studies are mostly in Primary Myelofibrosis · Neoplasms, led by Sumitomo Pharma.

Furthest: phase 2, since Nov 8, 20194 company-led studies, 1 open or runningNext primary completion: Apr 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sumitomo Pharma41 open or runningphase 2since Nov 8, 2019Oct 19, 2018Apr 30, 2027phase 2 · NCT04176198

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2018First study: phase 1 study in NeoplasmsFirst studyNCT03715504 · 22 enrolled · United States
  2. Nov 8, 2019Phase 2 study in Primary MyelofibrosisNCT04176198 · 240 planned · United States, Australia, Belgium and more
  3. Apr 22, 2024Phase 1 study in HealthyNCT06389955 · 12 enrolled · United States
  4. Mar 19, 2026Phase 1 study in Primary MyelofibrosisNCT07492355 · 24 enrolled · United States

Ahead

  1. Apr 30, 2027Primary completion: phase 2 study in Primary MyelofibrosisNCT04176198

TargetBeta

PIM1 →read by rule
“An orally available, second-generation and selective ATP-competitive inhibitor of proviral integration site for Moloney murine leukemia virus (PIM) kinases, ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07492355Primary Myelofibrosis · United States1CompletedMay 31, 202424
NCT06389955Healthy · United States1CompletedAug 1, 202312
NCT04176198Primary Myelofibrosis · United States, Australia, Belgium and more2RecruitingApr 30, 2027240
NCT03715504Neoplasms · United States1CompletedMar 30, 202122

How it is read

Names in the registry

  • “TP-3654”, 2 entries
  • “Nusivertib”, 1 entry
  • “TP 3654”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.